Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.

Kewen HeNahum Puebla-OsorioHampartsoum B BarsoumianDuygu SezenZahid RafiqThomas S RiadYun HuAiling HuangTiffany A VossClaudia S Kettlun LeytonLily Jae SchudaEthan HsuJoshua HeiberMaria-Angelica CortezJames W Welsh

Published in: Journal of experimental & clinical cancer research : CR (2024)

The addition of Nemvaleukin therapy may enhance responses to RT alone and in combination with anti-PD1.

Keyphrases

radiation therapy
dna damage
replacement therapy
squamous cell carcinoma
radiation induced
bone marrow
oxidative stress
cell therapy